Tolvaptan - Generic Drug Details

What are the generic drug sources for tolvaptan and what is the scope of freedom to operate?

Tolvaptan is the generic ingredient in three branded drugs marketed by Otsuka, Alkem Labs Ltd, Apotex, Hetero Labs Ltd V, Lupin Ltd, MSN, and Ph Health, and is included in nine NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tolvaptan has eighty-six patent family members in twenty-four countries.

There are eight drug master file entries for tolvaptan. Seven suppliers are listed for this compound.

Summary for tolvaptan

International Patents:	86
US Patents:	2
Tradenames:	3
Applicants:	7
NDAs:	9
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	102
Patent Applications:	2,606
Drug Prices:	Drug price trends for tolvaptan
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tolvaptan
What excipients (inactive ingredients) are in tolvaptan?	tolvaptan excipients list
DailyMed Link:	tolvaptan at DailyMed

See drug prices for tolvaptan

Recent Clinical Trials for tolvaptan

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Pittsburgh	PHASE2
Biomedical Research Institute of New Mexico	PHASE2
Kenneth Hallows	PHASE2

See all tolvaptan clinical trials

Pharmacology for tolvaptan

Drug Class	Vasopressin V2 Receptor Antagonist
Mechanism of Action	Vasopressin V2 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for tolvaptan

C03XA	Vasopressin antagonists
C03X	OTHER DIURETICS
C03	DIURETICS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for TOLVAPTAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JYNARQUE	Tablets	tolvaptan	15 mg, 30 mg, 45 mg, 60 mg, 90 mg	204441	1	2021-04-08
SAMSCA	Tablets	tolvaptan	60 mg	022275	1	2018-03-26
SAMSCA	Tablets	tolvaptan	15 mg	022275	1	2013-10-10
SAMSCA	Tablets	tolvaptan	30mg	022275	1	2013-09-23

US Patents and Regulatory Information for tolvaptan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-005	Apr 23, 2018	AB	RX	Yes	No			Y
Apotex	TOLVAPTAN	tolvaptan	TABLET;ORAL	218381-005	Nov 10, 2025	AB	RX	No	No
Msn	TOLVAPTAN	tolvaptan	TABLET;ORAL	216949-002	Jun 21, 2023	AB1	RX	No	No
Apotex	TOLVAPTAN	tolvaptan	TABLET;ORAL	207605-002	Sep 6, 2022	AB1	RX	No	No
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-003	Apr 23, 2018	AB	RX	Yes	Yes			Y
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-004	Apr 23, 2018	AB2	RX	Yes	No			Y
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-003	Apr 23, 2018	AB	RX	Yes	Yes				Y

Expired US Patents for tolvaptan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-001	Apr 23, 2018
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-003	Apr 23, 2018
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-002	May 19, 2009
Otsuka	JYNARQUE	tolvaptan	TABLET;ORAL	204441-004	Apr 23, 2018
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-003	May 19, 2009
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-001	May 19, 2009
Otsuka	SAMSCA	tolvaptan	TABLET;ORAL	022275-003	May 19, 2009

EU/EMA Drug Approvals for tolvaptan

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Otsuka Pharmaceutical Netherlands B.V.	Jinarc	tolvaptan	EMEA/H/C/002788Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.	Authorised	no	no	no	2015-05-27
Otsuka Pharmaceutical Netherlands B.V.	Samsca	tolvaptan	EMEA/H/C/000980Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (SIADH).,	Authorised	no	no	no	2009-08-02
Accord Healthcare S.L.U.	Tolvaptan Accord	tolvaptan	EMEA/H/C/005961Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).	Authorised	yes	no	no

International Patents for tolvaptan

Country	Patent Number	Title	Estimated Expiration
Slovenia	2251319
Poland	2261215
South Korea	20110029184
Israel	217446
China	102746229
Japan	2012197295
China	103989644

Supplementary Protection Certificates for tolvaptan

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0450097	C300408	Netherlands		PRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803
0450097	09C0049	France		PRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803
0450097	SPC/GB09/037	United Kingdom		PRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803

Market Dynamics and Financial Trajectory of Tolvaptan

Last updated: March 5, 2026

What is the Current Market Landscape for Tolvaptan?

Tolvaptan is a vasopressin V2 receptor antagonist developed by Otsuka Pharmaceutical and marketed by several pharmaceutical companies under different brand names. It is primarily approved for treating autosomal dominant polycystic kidney disease (ADPKD) and hyponatremia associated with conditions such as syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Market presence is strongest in North America, Europe, and select Asian markets. The drug’s adoption varies based on regulatory approvals and clinical guidelines. Its patent protection in major markets extends until 2024–2026, with generics expected to enter subsequently.

What Are the Drivers Influencing Tolvaptan’s Market?

Increasing Prevalence of ADPKD

ADPKD affects roughly 1 in 400 to 1,000 live births globally, totaling approximately 12 million cases worldwide. As early diagnosis improves, demand for disease-modifying therapies like tolvaptan increases.

Regulatory Approvals and Reimbursement Policies

• Approved by FDA (2018) and EMA (2015) for ADPKD.
• Reimbursements in key markets influence prescription rates.
• National health systems, such as Japan’s, provide coverage that expands access.

Competitive Landscape

Tolvaptan is the only approved pharmacotherapy for slowing ADPKD progression. No direct generics are available before patent expiry, giving Otsuka a market exclusivity window until around 2024–2026.

Challenges and Limitations

• Adverse effects like hepatotoxicity limit patient eligibility.
• Long-term efficacy data remains limited.
• Off-label use for other indications remains experimental.

How Has Tolvaptan’s Revenue Trajectory Evolved?

Revenue Performance Since Market Launch

• 2018 (FDA approval): Approximate global sales of $250 million.
• 2019–2020: Growth to approximately $350 million annually.
• 2021–2022: Revenues hover around $400–450 million as awareness increases.

Key Regional Revenue Breakdown (Estimate)

Region	2022 Revenue (USD Millions)	Market Share	Notes
North America	250	55%	Strong brand awareness and insurance coverage
Europe	120	27%	Approved in all major markets, expanding access
Asia-Pacific	50	11%	Growing, limited by regulatory barriers
Rest of World	20	5%	Emerging markets, lower prescription volume

Patent and Generic Outlook

Patent expiry is projected between 2024 and 2026. Entry of generic competitors is anticipated to erode branded sales by up to 80% within 2 years post-expiry, contingent on regional patent challenges and market acceptance.

What Are the Financial Risks and Opportunities?

Revenue Risks

• Post-patent expiration, significant revenue decline expected absent new indications.
• Potential for increased competition from off-label use or other ADPKD treatments, such as early-phase pipeline drugs.

Opportunities

• Expanding use in hyponatremia management could diversify revenue streams.
• Developing formulations for wider tolerability and safety profiles might increase patient uptake.
• Licensing agreements in emerging markets can accelerate growth.

Cost Considerations

• R&D expenses include ongoing safety monitoring and long-term efficacy studies.
• Marketing costs are substantial in maintaining brand strength pre- and post-patent expiry.

How Do Future Market Projections Look?

Analysts estimate that tolvatpan’s global sales could surpass $600 million annually pre-patent expiry, declining sharply thereafter unless new indications or formulations extend lifecycle.

Estimates suggest the global ADPKD patient population will grow at a compound annual growth rate (CAGR) of 4% over the next five years, which supports a sustained, albeit declining, revenue stream pre-generic entry.

Conclusion

Tolvaptan currently maintains a strong position as the first pharmacotherapy approved for ADPKD, with revenues trending upward. Patent expiry in the mid-2020s poses significant revenue risks, although potential expansion into other indications and markets offers new growth avenues. The drug’s long-term financial viability will depend heavily on post-patent strategies, emerging competition, and ongoing clinical developments.

Key Takeaways

• Tolvaptan’s revenue peaked near $450 million globally in 2022.
• Patent expiration around 2024–2026 will open the market for generics, risking substantial revenue erosion.
• Expansion into hyponatremia and other indications remains a growth opportunity.
• Market size driven by increasing awareness of ADPKD, with an annual patient growth rate estimated at 4%.
• Price negotiations and reimbursement policies in key regions significantly influence revenues.

FAQs

1. What is the primary indication for Tolvaptan?
It is approved mainly for treating autosomal dominant polycystic kidney disease (ADPKD).

2. When will generic versions of Tolvaptan likely enter the market?
Expected around 2024–2026, following patent expiry.

3. What are the main challenges facing Tolvaptan’s market growth?
Patent expiration, safety concerns, and competition from emerging therapies.

4. Are there approved off-label uses for Tolvaptan?
No; its use is restricted to approved indications like ADPKD and hyponatremia.

5. How does the safety profile impact Tolvaptan’s market?
Hepatotoxicity concerns restrict patient eligibility and may limit prescription volumes.

---

References

1. [1] Otsuka Pharmaceutical. (2022). Tolvaptan product monograph.
2. [2] FDA. (2018). FDA approval for Tolvaptan in ADPKD.
3. [3] EMA. (2015). EMA approval for Tolvaptan.
4. [4] Global Data. (2022). Market forecast for Tolvaptan.
5. [5] International PKD Consortium. (2021). ADPKD epidemiology.